TABLE 3

Individual Measurements of Tumor Volume and ¹⁸F-FDG Uptake at Baseline and Follow-up

Patient no.	Baseline						Follow-up						% viable cells
Patient no.	Glu.	Vol.	SUVmean	SUVmax	TLGmean	TLGmax	Glu.	Vol.	SUVmean	SUVmax	TLGmean	TLGmax	% viable cells
1	91	1,355.0	5.03	20.03	6,815.65	27,140.65	97	875.7	1.03	3.17	901.97	2,775.97	1
2	114	452.4	6.72	17.92	3,040.13	8,107.01	134	119.0	2.13	3.69	253.47	439.11	1
3	85	53.4	1.32	2.52	70.49	134.57	91	52.7	1.30	2.24	68.51	118.05	50
4	123	863.1	3.14	9.58	2,710.13	8,268.50	93	1,027.0	2.90	7.33	2,978.30	7,527.91	20
5	87	728.1	2.52	10.41	1,834.81	7,579.52	79	805.4	2.31	7.00	1,860.47	5,637.80	70
6	80	34.5	2.36	4.62	81.42	159.39	88	8.7	1.21	1.87	10.53	16.27	15
7	93	148.9	1.21	3.59	180.17	534.55	78	36.2	0.80	1.24	28.96	44.89	20
8	86	156.7	1.92	4.69	300.86	734.92	108	182.5	1.95	4.19	355.88	764.68	70
9	79	317.5	1.34	2.90	425.45	920.75	85	226.8	0.96	1.82	217.73	412.78	40
10	97	241.2	2.10	8.60	506.52	2,074.32	85	212.2	1.18	2.66	250.40	564.45	70
11	84	187.6	4.12	9.82	772.91	1,842.23	91	187.5	3.03	6.77	568.13	1,269.38	90
12	147	1,913.6	2.60	31.08	4,975.36	59,474.69	115	2,087.0	0.85	6.86	1,773.95	14,316.82	5
13	100	664.0	2.86	15.82	1,899.04	10,504.48	96	646.9	0.96	4.29	621.02	2,775.20	5
14	96	101.2	4.44	15.22	449.33	1,540.26	78	84.2	0.83	2.17	69.89	182.71	5
15	86	799.5	4.60	27.24	3,677.70	21,778.38	89	115.1	1.96	14.90	225.60	1,714.99	15
16	95	1,526.5	1.05	4.90	1,602.83	7,479.85	69	2,663.1	0.43	1.59	1,145.13	4,234.33	5
17	91	52.9	2.55	6.18	134.90	326.92	97	50.6	1.47	2.93	74.38	148.26	70
18	93	18.6	2.14	3.17	39.80	58.96	81	12.4	1.16	1.73	14.38	21.45	70
19	94	838.8	2.09	17.48	1,753.09	14,662.22	105	454.7	1.52	7.41	691.14	3,369.33	50
20	105	429.3	2.62	8.70	1,124.77	3,734.91	86	803.9	2.46	7.69	1,977.59	6,181.99	70